Sumitomo Mitsui Financial Group (TYO:8316) and its wholly owned subsidiary Sumitomo Mitsui Banking Corporation (SMBC) jointly established GoAhead Pitch, a video pitch platform, with Silicon Valley-based venture capital firm GoAhead Ventures.
GoAhead Pitch was launched in February, according to a Tokyo bourse filing on Monday.
GoAhead Fund III, a Delaware limited partnership, invested in AOI Biosciences via GoAhead Pitch. AOI Biosciences develops the β2GPI Neoself Antibody Test and supports the development of diagnostics and therapies targeting autoimmune diseases.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments